Evidence map›Paper›PMID 25339351›Full record

ArticleCancer research2014

Bioengineered implantable scaffolds as a tool to study stromal-derived factors in metastatic cancer models.

Francesca Bersani, Jungwoo Lee, Min Yu, Robert Morris, Rushil Desai, Sridhar Ramaswamy, Mehmet Toner, Daniel A Haber, Biju Parekkadan

Open access · bronzeAbstract read
In one paragraph

Article in Cancer research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
4.1field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 62 citations in OpenAlex.

  1. Article
  2. Mesothelin CAR T Cells Secreting Anti-FAP/Anti-CD3 Molecules Efficiently Target Pancreatic Adenocarcinoma and its Stroma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024
    Article
  3. An engineered niche delineates metastatic potential of breast cancer.Bioengineering & translational medicine · 2024
    Article
  4. Review
  5. The Applications and Challenges of the Development ofCellular and molecular bioengineering · 2023
    Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Implantable and Injectable Biomaterial Scaffolds for Cancer Immunotherapy.Frontiers in bioengineering and biotechnology · 2020
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Francesca BersaniCancer Center and Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts.
Jungwoo LeeCenter for Engineering in Medicine and Surgical Services, Massachusetts General Hospital, Harvard Medical School and the Shriners Hospitals for Children, Boston, Massachusetts.
Min YuCancer Center and Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts. Howard Hughes Medical Institute, Chevy Chase, Maryland.
Robert MorrisCancer Center and Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts.
Rushil DesaiCancer Center and Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts.
Sridhar RamaswamyCancer Center and Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts.
Mehmet TonerCenter for Engineering in Medicine and Surgical Services, Massachusetts General Hospital, Harvard Medical School and the Shriners Hospitals for Children, Boston, Massachusetts.
Daniel A HaberCancer Center and Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts. Howard Hughes Medical Institute, Chevy Chase, Maryland. haber@helix.mgh.harvard.edu biju_parekkadan@hms.harvard.edu.
Biju ParekkadanCenter for Engineering in Medicine and Surgical Services, Massachusetts General Hospital, Harvard Medical School and the Shriners Hospitals for Children, Boston, Massachusetts. Harvard Stem Cell Institute, Boston, Massachusetts. haber@helix.mgh.harvard.edu biju_parekkadan@hms.harvard.edu.
Massachusetts General Hospital · USShriners Hospitals for Children - Erie · USHoward Hughes Medical Institute · US

Funding

Bio-MicroElectroMechanical Systems Resource CenterP41EB002503 · NIBIB · MASSACHUSETTS GENERAL HOSPITAL · PI TONER, MEHMET · 2004 to 2018
$17.4M
Modeling Metastasis and Acquired Drug Resistance Using Circulating Tumor CellsR01CA129933 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI Daniel A. Haber · 2008 to 2026
$7.5M
Artificial, Humanized Stem Cell NichesR01EB012521 · NIBIB · RUTGERS, THE STATE UNIV OF N.J. · PI PAREKKADAN, BIJU · 2011 to 2021
$6.0M
Elucidating Essential Components of Bone Marrow MetastasisR00CA163671 · NCI · UNIVERSITY OF MASSACHUSETTS AMHERST · PI LEE, JUNGWOO · 2014 to 2016
$740k
Peripheral Tissue Antigen Display by Mesenchymal Stem CellsK01DK087770 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI PAREKKADAN, BIJU · 2010 to 2014
$682k
Elucidating Essential Components of Bone Marrow MetastasisK99CA163671 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI LEE, JUNGWOO · 2012 to 2013
$179k
Howard Hughes Medical InstituteNCI NIH HHS K99 CA163671NCI NIH HHS K99CA163671NCI NIH HHS R00 CA163671NCI NIH HHS R01 CA129933NCI NIH HHS R01CA129933NIBIB NIH HHS P41 EB002503NIBIB NIH HHS R01 EB012521NIBIB NIH HHS R01EB012521NIDDK NIH HHS K01 DK087770NIDDK NIH HHS K01DK087770
6 · The paper itself

Abstract

Modeling the hematogenous spread of cancer cells to distant organs poses one of the greatest challenges in the study of human metastasis. Both tumor cell-intrinsic properties as well as interactions with reactive stromal cells contribute to this process, but identification of relevant stromal signals has been hampered by the lack of models allowing characterization of the metastatic niche. Here, we describe an implantable bioengineered scaffold, amenable to in vivo imaging, ex vivo manipulation, and serial transplantation for the continuous study of human metastasis in mice. Orthotopic or systemic inoculation of tagged human cancer cells into the mouse leads to the release of circulating tumor cells into the vasculature, which seed the scaffold, initiating a metastatic tumor focus. Mouse stromal cells can be readily recovered and profiled, revealing differential expression of cytokines, such as IL1β, from tumor-bearing versus unseeded scaffolds. Finally, this platform can be used to test the effect of drugs on suppressing initiation of metastatic lesions. This generalizable model to study cancer metastasis may thus identify key stromal-derived factors with important implications for basic and translational cancer research.

Indexed as

Neoplasm MetastasisNeoplasm TransplantationAnimalsBiomedical EngineeringHumansInterleukin-1betaMiceNeoplasmsStromal CellsTissue ScaffoldsIL1B protein, mouseInterleukin-1beta

Identifiers

PMID25339351
PMCPMC4267901
OpenAlexW1963979299

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.